Daiichi Sankyo

Daiichi Sankyo Demonstrates Breadth and Depth of Oncology Portfolio Across Multiple Cancers with New Data at ESMO Asia, SABCS and ASH

Retrieved on: 
Friday, December 1, 2023
Research, Genetics, Clinical Trials, Biotechnology, Health, Pharmaceutical, General Health, Science, Oncology, Lung, American Society of Hematology, Breast, Annual general meeting, Bone marrow, Fulvestrant, ASH, Acute myeloid leukemia, JST, ADC, Patient, Anastrozole, Lung cancer, TSE, Daiichi Sankyo, HER2, MD, R, AML, Cancer, Society, PTCL, NSCLC, Pharmaceutical industry

Daiichi Sankyo (TSE: 4568) will present new clinical research across its oncology portfolio in multiple types of solid and blood cancers at the 2023 ESMO Asia Congress (#ESMOAsia23), San Antonio Breast Cancer Symposium (#SABCS23) and American Society of Hematology (#ASH23) Annual Meeting prior to its annual R&D Day.

Key Points: 
  • Daiichi Sankyo (TSE: 4568) will present new clinical research across its oncology portfolio in multiple types of solid and blood cancers at the 2023 ESMO Asia Congress (#ESMOAsia23), San Antonio Breast Cancer Symposium (#SABCS23) and American Society of Hematology (#ASH23) Annual Meeting prior to its annual R&D Day.
  • “Our goal is to push the boundaries of science to change the way cancer is treated,” said Ken Takeshita, MD, Global Head, R&D, Daiichi Sankyo.
  • Daiichi Sankyo will hold its annual R&D Day for investors, analysts and media on Monday, December 11 at 5:30 - 7:00 pm EST/Tuesday, December 12 at 7:30 - 9:00 am JST.
  • Company executives will provide highlights of Daiichi Sankyo’s research data presented at SABCS and ASH, as well as updates on the company’s R&D strategy.

Susan G. Komen® West Palm Beach MORE THAN PINK Walk Raises Funds for Patient Care Services and Breast Cancer Health Equity

Retrieved on: 
Wednesday, December 13, 2023
Carbon, ITHINK Financial Amphitheatre, WPTV, Health equity, Research, Ford, Bank, Light, Federation, Disease, State, Breast cancer, Patient, La Croix, Latinx, Tears, Good Samaritan Hospital, Carbon Health, Palm Beach International Raceway, Daiichi Sankyo, Hubbard Broadcasting, PALM, Laughter, Opening ceremony, Florida Power & Light, Bank of America, THAN, Birth control, New York Post, Walgreens

WEST PALM BEACH, Fla., Dec. 13, 2023 /PRNewswire/ -- Susan G. Komen ®, the world's leading breast cancer organization, will hold the annual West Palm Beach MORE THAN PINK Walk on Saturday, January 27, 2024, at The Meyer Amphitheatre.

Key Points: 
  • WEST PALM BEACH, Fla., Dec. 13, 2023 /PRNewswire/ -- Susan G. Komen ®, the world's leading breast cancer organization, will hold the annual West Palm Beach MORE THAN PINK Walk on Saturday, January 27, 2024, at The Meyer Amphitheatre.
  • This signature event enables Komen to raise critical funds that provide direct support to breast cancer patients, fund groundbreaking research, empower health equity initiatives nationwide, and advocate for change at both the state and federal government levels.
  • "We are excited to host the annual West Palm Beach MORE THAN PINK Walk this year and provide a community for all individuals impacted by breast cancer," said Sean Gross, State Executive Director at Susan G. Komen.
  • "West Palm Beach has a large Latinx community and breast cancer is the leading cause of cancer death among Hispanic women in the U.S. We look forward to raising funds that advance health equity outcomes, provide patient navigation services, and break down the barriers that create poor breast health outcomes for these communities."

VANFLYTA® Approved in the EU as the First FLT3 Inhibitor Specifically for Patients with Newly Diagnosed FLT3-ITD Positive AML

Retrieved on: 
Thursday, November 9, 2023
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, QT interval, Cardiac arrest, National Center for Health Research, Acute myeloid leukemia, ECG, European Commission, Hypokalemia, Committee, European Directive on Traditional Herbal Medicinal Products, Febrile neutropenia, MD, Professor, News, University Hospital Heidelberg, EC, Maintenance, Pneumonia, Arrhythmia, Ventricular fibrillation, ALAN, Civil service commission, Daiichi Sankyo, Risk, TSE, HR, Leukemia, FLT3, Committee for Medicinal Products for Human Use, Safety, German Cancer Research Center, European, Patient, Death, Neutropenia, AML, Nursing, Pharmaceutical industry, EU, Lancet

VANFLYTA is the first FLT3 inhibitor approved in the EU specifically for the treatment of patients with newly diagnosed FLT3-ITD positive AML, which represents about 25 to 30% of all new AML cases.1,2

Key Points: 
  • VANFLYTA is the first FLT3 inhibitor approved in the EU specifically for the treatment of patients with newly diagnosed FLT3-ITD positive AML, which represents about 25 to 30% of all new AML cases.1,2
    The authorization by the European Commission (EC) follows the positive opinion of the Committee for Medicinal Products for Human Use and is based on the results of the QuANTUM-First trial, which were published in The Lancet .
  • The most common grade 3 or 4 treatment emergent adverse events (occurring in ≥ 10% of patients) were febrile neutropenia (43%), hypokalemia (19%), neutropenia (18%) and pneumonia (11%).
  • QTcF > 500 ms occurred in 2.3% of patients receiving VANFLYTA and 0.8% of patients discontinued VANFLYTA due to QT prolongation.
  • Two (0.8%) patients receiving VANFLYTA experienced cardiac arrest with recorded ventricular fibrillation on ECG (one with fatal outcome), both in the setting of severe hypokalemia.

ISoP New Board of Trustees Members Announced

Retrieved on: 
Wednesday, November 8, 2023
Research, Technology, Health Technology, Software, Biotechnology, Pharmaceutical, Health, Data Management, Science, Artificial Intelligence, Simulations Plus, FDA, Eli Lilly and Company, SLP, Merck, Trustee, Growth, Daiichi Sankyo, Utta Isop, Pharmacology, International Society, Pharmaceutical industry

Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation solutions for the pharmaceutical and biotechnology industries, announced today that Amparo de la Peña , Vice President of Pharmacometrics, has been elected to the International Society of Pharmacometrics (ISoP) Board of Trustees.

Key Points: 
  • Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation solutions for the pharmaceutical and biotechnology industries, announced today that Amparo de la Peña , Vice President of Pharmacometrics, has been elected to the International Society of Pharmacometrics (ISoP) Board of Trustees.
  • “Amparo is an experienced pharmacometrician, having spent more than 20 years working for Eli Lilly and Company before going into consulting and serving small biotechs and big pharma companies in diverse therapeutic areas.
  • “We were fortunate to have so many distinguished candidates whose visionary ideas about how to grow ISoP were inspiring,” said Jennifer Pastore Monroy, Executive Director of ISoP.
  • “We are excited for the energy, enthusiasm, and perspectives [our new Trustees] will bring to the Board.”
    The newly elected Trustees will assume their roles effective January 1, 2024.

vTv Therapeutics Appoints Thomas Strack, M.D., as Chief Medical Officer

Retrieved on: 
Thursday, November 2, 2023
Knowledge, Medical Affairs Bureau, FDA, Therapy, Clinical research, National Association Medical Staff Services, Breakthrough, Eli Lilly, Daiichi Sankyo, Research, Drug development, Eli Lilly and Company, VTV, T1D, Patient, Consultant, University of Mainz, Insulin, Pharmaceutical industry, Oncology, Pfizer

as Chief Medical Officer, effective immediately.

Key Points: 
  • as Chief Medical Officer, effective immediately.
  • “I am pleased to welcome Dr. Strack to the vTv team,” said Paul Sekhri, President and Chief Executive Officer of vTv Therapeutics.
  • Most recently, he served as Chief Medical Officer of Faeth Therapeutics Inc., a clinical stage developer of metabolic oncology therapies.
  • He also served as Consultant in Medical Affairs at Omeros Corporation, a clinical stage biopharmaceutical company focused on small-molecule and protein therapeutics for immunologic disorders.

Change in Leadership at Daiichi Sankyo Europe

Retrieved on: 
Monday, November 6, 2023
Biotechnology, Health, Pharmaceutical, Cardiology, Oncology, AstraZeneca, Heart, Carbon, Wind, Multimedia, Quality of life, Growth, Daiichi Sankyo, Head, Patient, Accounting, Cardiovascular disease, Journal of Business Finance & Accounting, Pharmaceutical industry, Fine chemical, European

Today, Daiichi Sankyo Europe GmbH, the European headquarter organisation of the Japanese pharmaceutical company Daiichi Sankyo Co., Ltd., announced the appointment of its new Managing Director Masahiro Kato and new Head of the European Speciality Business Unit, Oliver Appelhans.

Key Points: 
  • Today, Daiichi Sankyo Europe GmbH, the European headquarter organisation of the Japanese pharmaceutical company Daiichi Sankyo Co., Ltd., announced the appointment of its new Managing Director Masahiro Kato and new Head of the European Speciality Business Unit, Oliver Appelhans.
  • His 35 years at Daiichi Sankyo spans roles in Finance, Accounting and most recently Sustainability Promotion, an increasingly important area for Daiichi Sankyo.
  • He will also be a strong advocate for the patients Daiichi Sankyo Europe seeks to impact, in the spirit of Daiichi Sankyo’s purpose which is to contribute to the enrichment of quality of life around the world.
  • Besides the strong business performance of Daiichi Sankyo Europe, I am also very impressed with the organisation’s focus on sustainability initiatives, a topic that is close to my heart.

HER CHOICE Digital Counselling Tool Connects Patients and Physicians in the Fight Against HER2-Positive Metastatic Breast Cancer

Retrieved on: 
Thursday, October 26, 2023
CONNECT, PSP, Digital, Connecting Communities, AstraZeneca, Hope, Oncology, Physician, Tool, HER, Entrepreneurship, National Management Association, Quality of life, CBCN, Disease, Daiichi Sankyo, Caregiver, Breast cancer, Patient, Communication, Pharmaceutical industry, Nursing

For patients, it offers a comprehensive resource to better understand their treatment options and actively participate in their healthcare decisions.

Key Points: 
  • For patients, it offers a comprehensive resource to better understand their treatment options and actively participate in their healthcare decisions.
  • It streamlines communication, helping both parties make important decisions about treatment plans and navigate the complexities of HER2-positive metastatic breast cancer."
  • "AstraZeneca is proud to support the launch of the HER CHOICE Digital Counselling Tool," says Paul Vardanis, National Manager Professional Education at AstraZeneca.
  • "This tool represents a significant advancement in providing patients and healthcare practitioners with the resources they need to make informed decisions in the fight against HER2-positive metastatic breast cancer."

Merck Announces Third-Quarter 2023 Financial Results

Retrieved on: 
Thursday, October 26, 2023
Cardiology, Biotechnology, Pharmaceutical, Oncology, Health, Diabetes, Infectious Diseases, Clinical Trials, Ezetimibe, Vaccine, Prometheus, News, Merck, GAAP, ADC, Daiichi Sankyo, EPS, Webcast, Investment, Pharmaceutical industry, Fine chemical, Bank, Rare-earth element, Imago

These items are inherently difficult to forecast and could have a significant impact on the company’s future GAAP results.

Key Points: 
  • These items are inherently difficult to forecast and could have a significant impact on the company’s future GAAP results.
  • Merck now expects full-year sales to be between $59.7 billion and $60.2 billion, including a negative impact of foreign exchange of approximately 2 percentage points, at mid-October 2023 exchange rates.
  • Merck now expects its full-year non-GAAP EPS to be between $1.33 and $1.38, including a negative impact of foreign exchange of approximately 6 percentage points, at mid-October 2023 exchange rates.
  • A replay of the webcast, along with the sales and earnings news release, supplemental financial disclosures, prepared remarks and slides highlighting the results, will be available at www.merck.com .

Global Acute Myeloid Leukemia (AML) Treatment Market Trends and Forecasts, 2020-2022 & 2023-2028 with Profiles of Major Players - AbbVie, Daiichi Sankyo, GlaxoSmithKline, Pfizer and Servier - ResearchAndMarkets.com

Retrieved on: 
Tuesday, October 24, 2023
Pharmaceutical, Health, Oncology, Incidence, Mortality, Haematopoietic system, GSK plc, Pfizer, Growth, Daiichi Sankyo, Risk, COVID-19, DSM-IV codes, Radiation, Anthracycline, Bone marrow, Lonrho, AbbVie, AML, Pharmaceutical industry, Vaccine, Dentistry, Laboratoires Servier

The "Global Acute Myeloid Leukemia (AML) Treatment Market: Forecast and Trends" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Acute Myeloid Leukemia (AML) Treatment Market: Forecast and Trends" report has been added to ResearchAndMarkets.com's offering.
  • The global AML treatment market was valued at nearly $3.5 billion in 2022.
  • This study's primary objective is to conduct a comprehensive analysis of the AML treatment market, offering insights into its dynamics, prevailing trends, and the overall market landscape.
  • Technological advancements in the field of blood cancer have played a pivotal role in propelling the AML treatment market forward.

Datopotamab deruxtecan improved progression-free survival vs. chemotherapy in patients with previously treated non-small cell lung cancer in TROPION-Lung01 Phase III trial

Retrieved on: 
Monday, October 23, 2023
Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, FDA, Clinical Trials, DXD, Neoplasm, EGFR, NSCLC, AstraZeneca, Incidence, ESMO, Progression-free survival, Trae tha Truth, Fatigue, Stomatitis, Lung cancer, Congress, PFS, MD, Docetaxel, European Society for Medical Oncology, CRS, HIV disease progression rates, R, Nausea, ADC, Daiichi Sankyo, Risk, Histology, ORR, ILD, Anemia, Weakness, Cancer, Patient, OS, Death, Toxicity, Neutropenia, UCLA Health, Medical imaging, Fine chemical, Pharmaceutical industry

Median PFS was 4.4 months in patients treated with datopotamab deruxtecan versus 3.7 with docetaxel.

Key Points: 
  • Median PFS was 4.4 months in patients treated with datopotamab deruxtecan versus 3.7 with docetaxel.
  • Results also showed a confirmed objective response rate (ORR) of 26.4% in patients treated with datopotamab deruxtecan compared to an ORR of 12.8% with docetaxel.
  • Median PFS was 5.6 months in patients treated with datopotamab deruxtecan versus 3.7 with docetaxel.
  • At the March 29, 2023 data cut-off, 52 patients remained on treatment with datopotamab deruxtecan and 17 remained on docetaxel.